Bruker BioSciences, Bruker BioSpin, North Carolina Biotechnology Center, Precision Human Biolaboratory, ABRF, Miraculins, GWC Technologies, QPS | GenomeWeb
Bruker BioSciences Buying Bruker BioSpin, Renaming Itself Bruker
 
Bruker BioSciences this week said it will buy Bruker BioSpin for $914 million. Privately held BioSpin is owned by the Laukien family, who also owns 52 percent of Bruker BioSciences. Upon completion of the deal, the Laukien family will own 69 percent of the new firm, to be called Bruker.
 
Frank Laukien is president and CEO of Bruker BioSciences and will assume both roles with the combined company.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.